50 results on '"Deben, Guillermo"'
Search Results
2. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group
3. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study
4. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program
5. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors
6. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
7. Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin’s lymphoma in Spain
8. Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study
9. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
10. Results of Compassionate Therapy with Intrathecal Depot Liposomal Cytarabine in Acute Myeloid Leukemia Meningeosis
11. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkinʼs lymphoma patients at high risk of central nervous system disease in the rituximab era
12. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma
13. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: Frequency and prognosis in 467 patients without cranial irradiation for prophylaxis
14. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia
15. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 without cranial irradiation for prophylaxis
16. A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RAR∝-Positive Acute Promyelocytic Leukemia: Presented in part at the 40th meeting of the American Society of Hematology, Miami Beach, FL, December 4-8, 1998.
17. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
18. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
19. Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score.
20. Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)
21. Azacitidine in Older Patients with Acute Myeloid Leukemia (AML) and Adverse Karyotype. Subanalisis from the Alma Study
22. Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program
23. Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study
24. Long-Term Outcome Of 151 Patients With Relapsed APL Receiving Second-Line With Chemotherapy Or Arsenic Trioxide-Based Regimens
25. A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization
26. Bendamustine In Combination With Rituximab As First-Line Treatment For Indolent Non-Hodgkin Lymphoma: Retrospective Analysis Of An Spanish Registry
27. Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators
28. Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance
29. Clofarabine in Acute Myeloid Leukemia. the Spanish Experience
30. Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)
31. Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups.
32. Prognostic Significance of Promoter Methylation of Multiple Genes in Germinal Center Hyperplasia (GCH) and Lymphomas of Germinal Center Origin.
33. Efficacy and Safety of Rituximab in Adult Patients with Idiopathic Relapsed or Refractory Thrombotic Thrombocytopenic Purpura (TTP). Results of a Spanish Multicenter Study.
34. R-ESHAP as Salvage Therapy for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Spanish GEL-TAMO Multicenter Study.
35. Promoter Methylation of Multiple Genes in Diffuse Large Cell Lymphoma (DLCL), Follicular Lymphoma (FL) and Bening Follicular Hyperplasia (BFH).
36. Secondary Acute Myeloid Leukemia and Myelodysplastic Syndromes Following ATRA and Anthracycline Monochemotherapy Treatment for Acute Promyelocytic Leukemia.
37. Comparison of Intensive Chemotherapy, Allogeneic, or Autologous Stem-Cell Transplantation As Postremission Treatment for Children With Very High Risk Acute Lymphoblastic Leukemia: PETHEMA ALL-93 Trial
38. Compassionate Use of Intrathecal Depot Cytarabine (DepoCyte®) in Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): Report of 11 Cases.
39. Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis.
40. Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Children with Very High-Risk Acute Lymphoblastic Leukemia (VHR-ALL). Final Results of the PETHEMA ALL-93 Trial.
41. Treatment of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) with Concurrent Chemotherapy and Imatinib Mesylate.
42. Causes of Induction Failure in Newly Diagnosed Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Idarubicin (AIDA).
43. Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.
44. Exantema generalizado granulomatoso durante un tratamiento con factor estimulante de colonias de granulocitos
45. Diffuse Interstitial Lung Disease as a First Manifestation of Waldenström's Macroglobulinemia: Case Report and Review of the Literature
46. Enfermedad pulmonar intersticial difusa como primera manifestación de macroglobulinemia de Waldenström: descripción de un caso y revisión de la literatura
47. Central nervous system recurrence in adult patients with acute lymphoblastic leukemiaThe following institutions and clinicians participated in the study: Hospital Universitari Germans Trias i Pujol, Badalona (J. M. Ribera, J. M. Sancho, A. Oriol, and E. Feliu); Hospital Carlos Haya, Malaga (C. Bethencourt); Hospital Virgen del Rocio, Sevilla (R. Parody); Hospital Virgen de la Victoria, Malaga (M. J. Moreno and M. J. Queipo de Llano); Hospital Clinico Universitario, Salamanca (J. M. Hernandez‐Rivas); Hospital Clinico San Carlos, Madrid (E. del Potro); Hospital General, Alicante (C. Rivas and P. Fernandez‐Abellan); Hospital Clinico Universitario, Valencia (M. Tormo and M. J. Terol); Hospital Son Dureta, Palma de Mallorca (J. Besalduch and A. Novo); Hospital Universitario La Fe, Valencia (M. A. Sanz and F. Moscardo); Hospital Xeral, Lugo (J. Arias); Hospital Morales Meseguer, Murcia (J. M. Moraleda and I. Heras); Hospital Vall d'Hebron, Barcelona (J. Bueno and J. J. Ortega); Hospital Cli
48. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line
49. A randomized phase II study comparing consolidation with a single dose of 90 Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
50. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.